In a preclinical study, triple combination therapies targeting 4-1BB, OX40, and PD-L1 demonstrated prolonged survival in HCC-bearing mice, providing proof of concept for this combination [44]. Here, TNFRSF4 is linked to hepatocellular carcinoma.